volume 18 issue 4

High-Dose Buprenorphine Initiation: A Scoping Review

Stanley Wong
Nicholas Fabiano
Declan Webber
Robert A. Kleinman
Publication typeJournal Article
Publication date2024-05-17
scimago Q1
wos Q1
SJR1.188
CiteScore5.4
Impact factor3.2
ISSN19320620, 19353227
Abstract
Objective

The aim of the study is to review and synthesize the literature on high-dose buprenorphine initiation (>12-mg total dose on day of initiation).

Methods

A scoping review of literature about high-dose buprenorphine initiation was conducted. MEDLINE, Embase, PsycINFO, and Cochrane Central were searched. Randomized controlled trials, prospective and retrospective cohort studies, and case studies/reports published in English before February 13, 2023, were included.

Results

Fifteen studies reporting outcomes from 580 high-dose buprenorphine initiations were included. Eight studies were in inpatient settings, 3 in emergency departments, 3 in outpatient settings, and 1 in a first-responder setting. Four studies reported high-dose initiations among individuals exposed to fentanyl. There were no reported events of fatal or nonfatal overdose or respiratory depression, although adverse event reporting was inconsistent in published reports. The most reported side effects with high-dose buprenorphine initiation were nausea or vomiting (n = 17) and precipitated withdrawal (n = 7). The most serious reported adverse event was hypotension requiring oral hydration (n = 2). Most studies reported improvements in subjective or objective withdrawal symptoms. The duration of follow-up ranged from none to 8 months.

Conclusions

High-dose buprenorphine initiation has not been associated with reported cases of overdose or respiratory depression. However, the current literature about high-dose buprenorphine is limited by inconsistent side effect reporting, limited power to detect rare safety events such as respiratory depression, limited follow-up data, and few comparison studies between high-dose and regular initiation protocols. Further prospective data are needed to evaluate the safety and effectiveness of this initiation strategy.

Found 
Found 

Top-30

Journals

1
2
3
JAMA network open
3 publications, 37.5%
Addiction science & clinical practice
2 publications, 25%
Journal for Nurse Practitioners
1 publication, 12.5%
Journal of the Academy of Consultation-Liaison Psychiatry
1 publication, 12.5%
American Journal of Medicine Open
1 publication, 12.5%
1
2
3

Publishers

1
2
3
Elsevier
3 publications, 37.5%
American Medical Association (AMA)
3 publications, 37.5%
Springer Nature
2 publications, 25%
1
2
3
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
8
Share
Cite this
GOST |
Cite this
GOST Copy
Wong S. et al. High-Dose Buprenorphine Initiation: A Scoping Review // Journal of Addiction Medicine. 2024. Vol. 18. No. 4.
GOST all authors (up to 50) Copy
Wong S., Fabiano N., Webber D., Kleinman R. A. High-Dose Buprenorphine Initiation: A Scoping Review // Journal of Addiction Medicine. 2024. Vol. 18. No. 4.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1097/adm.0000000000001296
UR - https://journals.lww.com/10.1097/ADM.0000000000001296
TI - High-Dose Buprenorphine Initiation: A Scoping Review
T2 - Journal of Addiction Medicine
AU - Wong, Stanley
AU - Fabiano, Nicholas
AU - Webber, Declan
AU - Kleinman, Robert A.
PY - 2024
DA - 2024/05/17
PB - Ovid Technologies (Wolters Kluwer Health)
IS - 4
VL - 18
PMID - 38757944
SN - 1932-0620
SN - 1935-3227
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2024_Wong,
author = {Stanley Wong and Nicholas Fabiano and Declan Webber and Robert A. Kleinman},
title = {High-Dose Buprenorphine Initiation: A Scoping Review},
journal = {Journal of Addiction Medicine},
year = {2024},
volume = {18},
publisher = {Ovid Technologies (Wolters Kluwer Health)},
month = {may},
url = {https://journals.lww.com/10.1097/ADM.0000000000001296},
number = {4},
doi = {10.1097/adm.0000000000001296}
}